| pubmed-article:7741789 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7741789 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:7741789 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:7741789 | lifeskim:mentions | umls-concept:C0205276 | lld:lifeskim |
| pubmed-article:7741789 | lifeskim:mentions | umls-concept:C0185125 | lld:lifeskim |
| pubmed-article:7741789 | lifeskim:mentions | umls-concept:C0681814 | lld:lifeskim |
| pubmed-article:7741789 | lifeskim:mentions | umls-concept:C0205373 | lld:lifeskim |
| pubmed-article:7741789 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:7741789 | pubmed:dateCreated | 1995-6-7 | lld:pubmed |
| pubmed-article:7741789 | pubmed:abstractText | 5-Aminosalicylic acid-O-sulfate (5-ASA sulfate), a new agent for the treatment of ulcerative colitis and Crohn's disease of the large intestine, was investigated for its pharmacokinetic and toxicological properties, following local and systemic application. 5-ASA sulfate can be considered as a non-toxic agent after single oral intake in rats (14-day LD50 > 6000 mg/kg b.w.). Oral application of 2500 mg 5-ASA sulfate/kg b.w./d for 28 days to rats resulted in significantly increased body weight gain and food and water consumption. Alanine aminotransferase and alkaline phosphatase values were elevated in high-dosed (2500 mg/kg b.w./d p.o.) males. Relative liver weights were significantly increased in high-dosed males and females and the macroscopical inspection revealed thickened liver margins. The no-effect level following 28 days of oral application to rats was determined as 500 mg 5-ASA sulfate/kg b.w./d. In acute local tolerance studies in rabbits, 5-ASA sulfate is rated as non-irritant to the skin and the eye. After a single oral administration of 1800 mg 5-ASA sulfate to 5 healthy human test subjects, 5-ASA sulfate was almost completely metabolized by all test subjects within 3 days; mean urinary and faecal excretion of unchanged 5-ASA sulfate amounted to only 6.7% of the administered dose. A high faecal excretion of the active metabolite 5-aminosalicylic acid (5-ASA) (21.2% of the administered dose) and a low urinary excretion (1.4% of the administered dose) were observed. | lld:pubmed |
| pubmed-article:7741789 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7741789 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7741789 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7741789 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7741789 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7741789 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7741789 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7741789 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:7741789 | pubmed:issn | 0004-4172 | lld:pubmed |
| pubmed-article:7741789 | pubmed:author | pubmed-author:HerzogRR | lld:pubmed |
| pubmed-article:7741789 | pubmed:author | pubmed-author:LeuschnerJJ | lld:pubmed |
| pubmed-article:7741789 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7741789 | pubmed:volume | 45 | lld:pubmed |
| pubmed-article:7741789 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7741789 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7741789 | pubmed:pagination | 300-3 | lld:pubmed |
| pubmed-article:7741789 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:meshHeading | pubmed-meshheading:7741789-... | lld:pubmed |
| pubmed-article:7741789 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7741789 | pubmed:articleTitle | Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-O-sulfate following local and systemic application. | lld:pubmed |
| pubmed-article:7741789 | pubmed:affiliation | Henning Berlin GmbH, Germany. | lld:pubmed |
| pubmed-article:7741789 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7741789 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7741789 | pubmed:publicationType | In Vitro | lld:pubmed |
